ЗАКЛЮЧИТЕЛЬНЫЙ МЕТААНАЛИЗ ИССЛЕДОВАНИЯ ЕРС (EARLY PROSTATE CANCER)
https://doi.org/10.17650/1726-9776-2009-5-2-74
Abstract
Заключительный метаанализ исследования ЕРС (Early Prostate Cancer)
References
1. http://clinicaltrials.gov/ct2/show/NCT 00657904?term=bicalutamide&rank=4
2. See W.A., Wirth M.P., McLeod D.G. Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the early prostate cancer program. J Urol 2002;168: 429—35.
3. Wirth M.P., See W.A, McLeod D.G. Bicalutamide 150 mg in addition to stan- dard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the early prostate cancer program at median followup of 5.4 years. J Urol 2004;172: 1865—70.
4. Онкоурология, спецвыпуск 2006;(2):13. 5. McLeod D.G., Iversen P., See W.A. et al. Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer. BJUI 2005;97:247—54.
Review
For citations:
. Cancer Urology. 2009;5(2):74. (In Russ.) https://doi.org/10.17650/1726-9776-2009-5-2-74
Views:
647
Email this article 